Inventiva (IVA) Long-Term Debt Repayments (2019 - 2025)
Inventiva's (IVA) quarterly Long-Term Debt Repayments came in at -$2.0 million in Q2 2025, down 59.95% year-on-year from -$5.1 million in Q2 2024, and down 5.93% quarter-over-quarter from -$1.9 million in Q4 2024.
Inventiva (IVA) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends
Inventiva's Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at -$2.0 million for Q2 2025.
- On a quarterly basis, Long-Term Debt Repayments fell 59.95% year-over-year to -$2.0 million in Q2 2025; TTM through Jun 2025 was -$3.3 million, a 154.98% decrease from a year earlier, with the FY2024 full-year figure at -$1.9 million, up 28.42% from the prior year.
- Long-Term Debt Repayments retreated to -$2.0 million in Q2 2025 per IVA's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at -$14871.6 in Q4 2021 and bottomed at -$2.7 million in Q4 2023.
- The 4-year median for Long-Term Debt Repayments is -$1.6 million (2023), against an average of -$1.4 million.
- Across the five-year window, Long-Term Debt Repayments surged 74.01% in 2021 and plunged 59.95% in 2025, its largest moves.
- Year by year, Long-Term Debt Repayments stood at -$14871.6 in 2021, then slumped by 17878.61% to -$2.7 million in 2023, then gained by 28.42% to -$1.9 million in 2024, then declined by 5.93% to -$2.0 million in 2025.
- Per Business Quant, the three latest IVA Long-Term Debt Repayments figures stand at -$2.0 million (Q2 2025), -$1.9 million (Q4 2024), and -$1.3 million (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2.03 Mn |
| Jun 30, 2025 | -2.03 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Dec 31, 2023 | -2.67 Mn |
| Dec 31, 2023 | -2.67 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Jun 30, 2023 | -1.58 Mn |
| Dec 31, 2021 | -14,871.62 |
| Dec 31, 2021 | -14,871.62 |
| Mar 31, 2021 | -15,681.07 |
| Mar 31, 2021 | -15,681.07 |
| Dec 31, 2020 | -57,229.91 |
| Dec 31, 2020 | -57,229.91 |
| Jun 30, 2020 | -15,420.44 |
| Jun 30, 2020 | -15,420.44 |
| Mar 31, 2020 | -37,533.93 |
| Mar 31, 2020 | -37,533.93 |